10:00 AM EDT, 09/26/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Thursday that its new drug submission for the vanzacaftor/tezacaftor/deutivacaftor cystic fibrosis triple combination treatment has been accepted for review by Health Canada.

The once-daily therapy is for cystic fibrosis patients at least six years old who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene, the company said.

The company said the new drug submission will be part of an aligned review with various entities in Canada.

Price: 461.66, Change: -0.10, Percent Change: -0.02